Life Sciences Tools and Services
Company Overview of MaRS Innovation
MaRS Innovation operates as a commercialization agent for the intellectual properties in the areas of therapeutics, medical device, diagnostic imaging, information, communications, and manufacturing and clean technologies to the inventors in Canada. The company has strategic partnerships with GlaxoSmithKline Inc.; CML HealthCare Inc.; Baxter International Inc.; and Pfizer Inc. MaRS Innovation was incorporated in 2008 and is based in Toronto, Canada.
101 College Street
Toronto, ON M5G 1L7
Founded in 2008
Key Executives for MaRS Innovation
Chief Financial Officer and Director
Director of Human Resources
Director of Commercialization
Compensation as of Fiscal Year 2014.
MaRS Innovation Key Developments
Johnson & Johnson Innovation, Janssen Inc. Announce New Collaborations with NEOMED and MaRS Innovation
Dec 10 13
Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada announced new collaborations with two Canadian early-stage drug technology development centers, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health. Through these collaborations, technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will work with NEOMED and MaRS Innovation to identify investment opportunities emerging from well-validated scientific research discoveries within their communities of academic institutions and biotechnology companies.
MaRS Innovation Presents at BioJapan 2013 World Business Forum, Oct-09-2013
Sep 25 13
MaRS Innovation Presents at BioJapan 2013 World Business Forum, Oct-09-2013 . Venue: Pacifico Yokohama, Yokohama, Japan.
MaRS Innovation Announces New Strategic Partnership with Pfizer Inc
Apr 22 13
MaRS Innovation announced the formation of a strategic partnership with Pfizer Inc. to advance early-stage technologies related to human health in therapeutics and diagnostics. Through this collaboration, MaRS Innovation and Pfizer will jointly identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation's 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals. Pfizer will provide funding over a three-year period to support promising individual projects based on their due diligence, which will be leveraged with financial support from MaRS Innovation. Together, it is intended to accelerate the development and validation of healthcare technologies within a highly innovative academic cluster in Canada. The partnership's shared vision for transformative technologies will benefit the health of Canadians and others around the world.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries